$APTO
Aptose Biosciences Inc. Stock $apto

$apto Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000117184322006964 Filed on November 01, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.609M	$3.424M	$3.606M
YoY Change	-12.1%	-5.05%	-37.18%
% of Gross Profit
Research & Development	$6.970M	$6.578M	$7.718M
YoY Change	-65.49%	-14.77%	2.65%
% of Gross Profit
Depreciation & Amortization	$28.00K	$30.00K	$36.00K
YoY Change	-36.36%	-16.67%	-2.7%
% of Gross Profit
Operating Expenses	$10.40M	$10.03M	$11.36M
YoY Change	-57.27%	-11.74%	-14.56%
Operating Profit
YoY Change
Interest Expense	$403.0K	$249.0K	$26.00K
YoY Change	1579.17%	857.69%	-48.0%
% of Operating Profit
Other Income/Expense, Net		$249.0K	$26.00K
YoY Change		857.69%	-42.22%
Pretax Income	-$10.00M	-$9.777M	-$11.33M
YoY Change	-58.89%	-13.73%	-14.47%
Income Tax
% Of Pretax Income
Net Earnings	-$10.00M	-$9.777M	-$11.33M
YoY Change	-58.89%	-13.73%	-14.46%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.11	-$0.11	-$0.13
Diluted Earnings Per Share	-$0.11	-$0.11	-$127.4K
COMMON SHARES
Basic Shares Outstanding	92.29M	92.29M	88.95M
Diluted Shares Outstanding		6.153M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.96M	$55.39M	$95.10M
YoY Change	-40.65%	-41.75%	-28.33%
Cash & Equivalents	$36.97M	$27.99M	$75.10M
Short-Term Investments	$9.989M	$27.40M	$20.01M
Other Short-Term Assets	$257.0K	$346.0K	$131.0K
YoY Change	93.23%	164.12%	13.91%
Inventory
Prepaid Expenses	$2.303M	$838.0K	$1.034M
Receivables
Other Receivables
Total Short-Term Assets	$49.52M	$56.58M	$96.27M
YoY Change	-39.42%	-41.23%	-28.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$211.0K	$251.0K	$353.0K
YoY Change	-34.67%	-28.9%	29.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.508M	$471.0K	$932.0K
YoY Change	91.37%	-49.46%	-29.02%
TOTAL ASSETS
Total Short-Term Assets	$49.52M	$56.58M	$96.27M
Total Long-Term Assets	$1.508M	$471.0K	$932.0K
Total Assets	$51.03M	$57.05M	$97.20M
YoY Change	-38.17%	-41.31%	-28.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.326M	$2.416M	$1.630M
YoY Change	272.34%	48.22%	6.61%
Accrued Expenses	$5.657M	$7.547M	$6.188M
YoY Change	-5.97%	21.96%	83.19%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.28M	$10.23M	$8.300M
YoY Change	50.28%	23.29%	52.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.002M	$1.000K	$218.0K
YoY Change	771.3%	-99.54%	-68.86%
Total Long-Term Liabilities	$1.002M	$1.000K	$218.0K
YoY Change	771.3%	-99.54%	-68.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.28M	$10.23M	$8.300M
Total Long-Term Liabilities	$1.002M	$1.000K	$218.0K
Total Liabilities	$13.29M	$10.23M	$8.518M
YoY Change	60.28%	20.15%	39.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$464.3M	-$454.3M	-$398.2M
YoY Change	9.89%	14.1%	16.28%
Common Stock	$437.5M	$437.5M	$429.8M
YoY Change	0.03%	1.79%	0.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$37.74M	$46.81M	$88.68M
YoY Change
Total Liabilities & Shareholders Equity	$51.03M	$57.05M	$97.20M
YoY Change	-38.17%	-41.31%	-28.14%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$10.00M	-$9.777M	-$11.33M
YoY Change	-58.89%	-13.73%	-14.46%
Depreciation, Depletion And Amortization	$28.00K	$30.00K	$36.00K
YoY Change	-36.36%	-16.67%	-2.7%
Cash From Operating Activities	-$8.651M	-$6.979M	-$8.059M
YoY Change	-46.08%	-13.4%	-2.55%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$181.0K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$17.57M	-$5.078M	-$4.000K
YoY Change	-187.88%	126850.0%	-99.91%
Cash From Investing Activities	$17.57M	-$5.078M	-$185.0K
YoY Change	-187.82%	2644.86%	-95.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	51.00K	$21.00K	$0.00
YoY Change	-22.73%		-100.0%
NET CHANGE
Cash From Operating Activities	-8.651M	-$6.979M	-$8.059M
Cash From Investing Activities	17.57M	-$5.078M	-$185.0K
Cash From Financing Activities	51.00K	$21.00K	$0.00
Net Change In Cash	8.973M	-$12.04M	-$8.248M
YoY Change	-124.93%	46.01%	-118.08%
FREE CASH FLOW
Cash From Operating Activities	-$8.651M	-$6.979M	-$8.059M
Capital Expenditures	$0.00	$0.00	$181.0K
Free Cash Flow	-$8.651M	-$6.979M	-$8.240M
YoY Change	-46.03%	-15.3%	-0.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92294734
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92294734
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92215024
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92215024
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15322000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q3	apto	Employee Stock Purchase Plan Maximum Payroll Deduction Percent EmployeeStockPurchasePlanMaximumPayrollDeductionPercent	0.15	pure
CY2022Q3	apto	Employee Stock Purchase Plan Stock Purchase Price Percent EmployeeStockPurchasePlanStockPurchasePricePercent	0.85	pure
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q3	us-gaap	Assets Assets	57048000	usd
CY2021Q4	us-gaap	Assets Assets	82525000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3641000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000882361
	dei	Entity Registrant Name EntityRegistrantName	Aptose Biosciences Inc.
	dei	Amendment Flag AmendmentFlag	false
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2416000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1699000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7547000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6016000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	270000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	459000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10233000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8174000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	115000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10887000	usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-32001
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1136802
CY2022Q3	us-gaap	Liabilities Liabilities	10234000	usd
	dei	Entity Address Address Line1 EntityAddressAddressLine1	51 Consumers Road, Suite 1105
	dei	Entity Address City Or Town EntityAddressCityOrTown	Toronto
	dei	Entity Address State Or Province EntityAddressStateOrProvince	ON
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	M2J 4R3
	dei	City Area Code CityAreaCode	647
	dei	Local Phone Number LocalPhoneNumber	479-9828
	dei	Security12b Title Security12bTitle	Common Shares, no par value
	dei	Trading Symbol TradingSymbol	APTO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21312000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25777000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3448000	usd
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	92294734
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27991000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39114000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	27402000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	40014000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	838000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2476000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	346000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	133000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	56577000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	81737000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	251000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	323000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	220000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	465000	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	471000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	788000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2021	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2021Q4	us-gaap	Liabilities Liabilities	8289000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	437469000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	437386000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68008000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	63673000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4333000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4316000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-454330000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422507000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46814000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	74236000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57048000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82525000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	0	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6578000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7718000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	10026000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	11359000	usd
	us-gaap	Operating Expenses OperatingExpenses	32199000	usd
	us-gaap	Operating Expenses OperatingExpenses	41099000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	254000	usd
CY2021Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	387000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	72000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-5000	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	4000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-11000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-3000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	249000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	376000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	69000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-9777000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11333000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	20000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-17000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9757000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11333000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31840000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41030000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92289000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88949000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92253000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88927000
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92289000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88949000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92253000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88927000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	74236000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4346000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31823000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	46814000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	118915000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	160000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10635000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	88680000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-9777000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11333000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1053000	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1828000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4346000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10635000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30000	usd
CY2021Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	92000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	111000	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	119000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	336000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	353000	usd
CY2022Q3	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	4000	usd
CY2021Q3	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	10000	usd
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	17000	usd
	apto	Interest On Lease Liabilities InterestOnLeaseLiabilities	35000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7000	usd
CY2021Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000	usd
CY2022Q3	apto	Interest Accrued On Investments InterestAccruedOnInvestments	-78000	usd
CY2021Q3	apto	Interest Accrued On Investments InterestAccruedOnInvestments	3000	usd
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	-85000	usd
	apto	Interest Accrued On Investments InterestAccruedOnInvestments	5000	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-825000	usd
CY2021Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-788000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1638000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1520000	usd
CY2022Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	225000	usd
CY2021Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	213000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	134000	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	139000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	411000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	416000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23000	usd
CY2021Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1284000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	717000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-541000	usd
CY2022Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1026000	usd
CY2021Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1905000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1531000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2086000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6979000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8059000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23671000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27260000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21000	usd
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	160000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	160000	usd
CY2022Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	5078000	usd
CY2021Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	4000	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-12517000	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	15000000	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2021Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	181000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	198000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5078000	usd
CY2021Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-185000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12493000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15198000	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-7000	usd
CY2021Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-4000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-10000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12043000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8248000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11123000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42298000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	40034000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83343000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39114000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	117393000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27991000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75095000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27991000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	75095000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"/><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">c.</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Significant accounting policies, estimates and judgments:</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 62pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">During the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2022, </em>there have been <em style="font: inherit;">no</em> changes to our significant accounting policies as described in our Annual Report on Form <em style="font: inherit;">10</em>-K for the fiscal year ended <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 62pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The preparation of the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 62pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and <em style="font: inherit;"> may </em>require accounting adjustments based on future occurrences.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 62pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q3	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-17000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	27402000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	40014000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"/><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">f.</p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Concentration of risk:</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 62pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The Company is subject to credit risk from the Company’s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <em style="font: inherit;">R1‑low</em> or A‑low investments and the Company invests only in highly rated corporations and treasury bills, which are capable of prompt liquidation.</p>
CY2022Q3	us-gaap	Cash Cash	874000	usd
CY2021Q4	us-gaap	Cash Cash	294000	usd
CY2022Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	27117000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	38820000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	135000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	140000	usd
CY2022Q3	apto	Prepaid Research And Development PrepaidResearchAndDevelopment	589000	usd
CY2021Q4	apto	Prepaid Research And Development PrepaidResearchAndDevelopment	632000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	249000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1844000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	838000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2476000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	40014000	usd
CY2021Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1860000	usd
CY2020Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1848000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	91000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	12000	usd
CY2022Q3	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1951000	usd
CY2021Q4	apto	Operating Lease Right Of Use Asset Gross OperatingLeaseRightOfUseAssetGross	1860000	usd
CY2022Q3	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	1731000	usd
CY2021Q4	apto	Amortization Of Rightof Use Assets AmortizationOfRightofUseAssets	1395000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	220000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	465000	usd
CY2022Q3	apto	Lessee Operating Lease Liability To Be Paid After Year One LesseeOperatingLeaseLiabilityToBePaidAfterYearOne	0	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	275000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1700000
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	27419000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	54519000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	78834000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1863000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2152000	usd
CY2022Q3	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	4929000	usd
CY2021Q4	apto	Research And Development Liabilities Current ResearchAndDevelopmentLiabilitiesCurrent	3520000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	755000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	344000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7547000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6016000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0514	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0537	pure
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	270000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	459000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	115000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	271000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	574000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	115000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	129000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	353000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	388000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	134000	usd
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	139000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	411000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	416000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-9777000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-11333000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-31823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-41030000	usd
CY2022Q3	apto	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	92289000
CY2021Q3	apto	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	88949000
	apto	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	92253000
	apto	Weighted Average Number Of Shares Outstanding Basic And Diluted Total WeightedAverageNumberOfSharesOutstandingBasicAndDilutedTotal	88927000
CY2022Q3	apto	Earnings Per Share Basic And Diluted Total EarningsPerShareBasicAndDilutedTotal	-0.11
CY2021Q3	apto	Earnings Per Share Basic And Diluted Total EarningsPerShareBasicAndDilutedTotal	-0.13
	apto	Earnings Per Share Basic And Diluted Total EarningsPerShareBasicAndDilutedTotal	-0.34
	apto	Earnings Per Share Basic And Diluted Total EarningsPerShareBasicAndDilutedTotal	-0.46
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	10858
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	15112000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.61
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6295000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.19
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2325000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.16
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19068000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10564000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17790000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y1M20D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11942000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4199000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.04
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	67000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1205000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.47
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14869000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8092000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13851000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.67
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3990000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	4000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0217	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0052	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.827	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.818	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.59
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6295000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4199000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1053000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1828000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4346000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10635000	usd

Files In Submission

Name	View Source	Status
apto-20220930_def.xml	Edgar Link	unprocessable
apto-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
apto20220930_10q_htm.xml	Edgar Link	completed
0001171843-22-006964-index-headers.html	Edgar Link	pending
0001171843-22-006964-index.html	Edgar Link	pending
0001171843-22-006964.txt	Edgar Link	pending
0001171843-22-006964-xbrl.zip	Edgar Link	pending
apto-20220930.xsd	Edgar Link	pending
apto20220930_10q.htm	Edgar Link	pending
ex_439394.htm	Edgar Link	pending
ex_439395.htm	Edgar Link	pending
ex_439396.htm	Edgar Link	pending
ex_439397.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
logo.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
apto-20220930_lab.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
apto-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APTO
Aptose Biosciences Inc. Stock $apto

2022 Q4 Form 10-Q Financial Statement

#000117184322006964 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO Aptose Biosciences Inc. Stock $apto

2022 Q4 Form 10-Q Financial Statement

#000117184322006964 Filed on November 01, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APTO
Aptose Biosciences Inc. Stock $apto